Two New Focused Business Units for Biologics and Oral Drug Delivery
Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced
delivery technologies and development solutions for drugs, biologics,
and consumer health products, today announced it has completed the
acquisition of Cook Pharmica LLC, an integrated provider of drug
substance and drug product manufacturing and related services. The
acquisition of this Bloomington, Indiana-based biologics contract
development and manufacturing organization substantially strengthens
Catalent’s position as a leader in biologics development and analytical
services, manufacturing and finished product supply. Their complementary
capabilities and expertise will help customers accelerate biologic drug
development programs and bring better treatments to patients worldwide.
Catalent intends to maximize the benefits of the acquisition through the
reorganization of its operations to create two new dedicated business
units that will sharpen the focus on growth, performance and customers’
needs.
First, recognizing the company’s substantially increased
biopharmaceutical and fill-finish capabilities and the importance of the
rapidly growing area of biologics, Catalent has created a business unit
focused on Biologics & Specialty Drug Delivery, to be led by Barry
Littlejohns as President. He will oversee eight Catalent facilities
focused on biologics development, manufacturing, analytical, and sterile
fill-finish and Catalent’s respiratory and ophthalmic business
platforms. Tedd Green, formerly President of Cook Pharmica, will now
serve as Senior Vice President, Catalent Bloomington.
Mr. Littlejohns has been with Catalent for 26 years, initially with its
predecessor RP Scherer, and most recently served as President of the
company’s former Drug Delivery Solutions business unit.
Second, Catalent has reorganized the remainder of its former Drug
Delivery Solutions business into a newly formed Oral Drug Delivery
business unit, to be led by Jonathan Arnold as President. Oral Drug
Delivery will bring together Catalent’s expertise and capabilities in
advanced delivery technologies and development solutions, including
formulation and analytical development, bioavailability enhancement
including micronization, hot melt extrusion and spray dry technologies,
controlled release, Zydis® orally disintegrating tablet
technology, and commercial supply across nine facilities.
Mr. Arnold has worked for leading life science organizations for over 23
years. These include RP Scherer, Patheon, and Catalent, where he has
held senior business leadership roles in Europe and the U.S. For the
past 6 years he has served as Vice President and General Manager for
Catalent’s Drug Delivery Solutions business unit.
“The establishment of these focused business units reflects the rapid
growth we are seeing across key markets, particularly for biologics and
differentiated dosage forms,” commented John Chiminski, Chair and
CEO of Catalent. “We have an exciting strategic plan to accelerate
our portfolio of capabilities, as evidenced by the recent growth
investments we have made, including multi-million-dollar site expansions
and the newly completed acquisition of Cook Pharmica. We are confident
that the experience and expertise of Barry, Jonathan, and Tedd will
provide valuable leadership as we move forward in this exciting phase of
our development.”
To arrange a meeting with Mr. Littlejohns or Mr. Arnold at CPhI in
Frankfurt, please contact Richard Kerns, Northern Exposure PR at richard@nepr.eu.
About Catalent
Catalent, Inc. (NYSE: CTLT) is the leading global provider of advanced
delivery technologies and development solutions for drugs, biologics and
consumer health products. With over 80 years serving the industry,
Catalent has proven expertise in bringing more customer products to
market faster, enhancing product performance and ensuring reliable
clinical and commercial product supply. Catalent employs over 10,000
people, including over 1,400 scientists, at more than 30 facilities
across five continents, and in fiscal 2017 generated over $2 billion in
annual revenue. Catalent is headquartered in Somerset, New Jersey. For
more information, visit www.catalent.com.
More
products. Better treatments. Reliably supplied.™
Forward-Looking Statements
This release contains both historical and forward-looking statements.
All statements other than statements of historical fact are, or may
be deemed to be, forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E
of the Securities Exchange Act of 1934, as amended. These
forward-looking statements generally can be identified by the use of
statements that include phrases such as “believe,” “expect,”
“anticipate,” “intend,” “estimate,” “plan,” “project,” “foresee,”
“likely,” “may,” “will,” “would,” or other words or phrases with similar
meanings. Similarly, statements that describe Catalent’s
objectives, plans, or goals are, or may be, forward-looking statements.
These statements are based on current expectations of future events. If
underlying assumptions prove inaccurate or unknown risks or
uncertainties materialize, actual results could vary materially from
Catalent’s expectations and projections. Such forward-looking statements
are subject to various risks and uncertainties, including risks relating
to the integration of Cook Pharmica into Catalent, risks associated with
potential dislocations arising from the business unit reorganization,
and those risks and uncertainties described under the section entitled
“Risk Factors” in Catalent’s Annual Report on Form 10-K for the fiscal
year ended June 30, 2017, filed with the Securities and Exchange
Commission (the “SEC”) on August 28, 2017, as such factors may be
updated from time to time in Catalent’s filings with the SEC related to
the acquisition, its financing, Catalent’s quarterly financial results,
or any other matter, which filings are accessible on the SEC’s website
at
www.sec.gov
.
Accordingly, there are or will be important factors that could cause
actual outcomes or results to differ materially from those indicated in
these statements. These factors should not be construed as exhaustive
and should be read in conjunction with the other cautionary statements
that are included in Catalent’s filings with the SEC. All
forward-looking statements speak only as of the date of this release or
as of the date they are made, and Catalent does not undertake to update
any forward-looking statement as a result of new information or future
events or developments except to the extent required by law.
For Catalent, Inc.
Media:
Chris Halling, +44 (0)7580 041073
chris.halling@catalent.com
or
Richard Kerns, +44 (0) 161 728 5880
richard@nepr.eu
or
Investors:
Thomas Castellano, +1 (732) 647 5013
thomas.castellano@catalent.com